Sort
78,016 grants matching “breast cancer”
Expression-Based Multi-Gene Signatures for CRC Recurrence and Chemoselection
$999,610Christopher Sears · Ambergen, Inc · R44 · FY2012 · CA
Expression-Based Multi-Gene Signatures for CRC Recurrence and Chemoselection
$999,610Christopher Sears · Ambergen, Inc · R44 · FY2010 · CA
OTHER FUNCTIONS SBIR PHASE II TOPIC 290 "RNAI SYNTHETIC LETHAL SCREEN IN CANCER
$999,596Alexandr Chenchik · Cellecta, Inc. · N44 · FY2012 · CA
A treatment drug for triple negative breast cancer
$999,562Zhi-Ren Liu · Proda Biotech, Llc · U44 · FY2022 · CA
A treatment drug for triple negative breast cancer
$999,562Zhi-Ren Liu · Proda Biotech, Llc · U44 · FY2023 · CA
SBIR Phase II: Cryogenic probe development and testing for post-lumpectomy margin ablation treatment
$999,545Dan Wittenberger · Senoguard, Inc. · · FY2024 · TIP
Fluorescein for Sentinel Lymph Node Detection
$999,419James M McGreevy · Vestan, Inc. · R42 · FY2010 · CA
Homology-directed repair: BRCA2 and RAD51 paralogs
$999,388Maria Jasin · Sloan-Kettering Inst Can Research · R35 · FY2023 · CA
Homology-directed repair: BRCA2 and RAD51 paralogs
$999,388Maria Jasin · Sloan-Kettering Inst Can Research · R35 · FY2022 · CA
A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome
$999,333Steven Isaacman · Nanometics, Llc · R44 · FY2019 · CA
Liver Specific Manganese Based MRI Contrast Agent
$999,330Vera Hoffman · Reveal Pharma · R44 · FY2021 · CA
WFUSM Macaca fascicularis SPF Breeding Colony
$999,315Janice D. Wagner · Wake Forest University Health Sciences · P40 · FY2008 · RR
PyroTIMER Technology: Enabling T-Cell Persistence in Immunosuppressive Tumor Microenvironments
$999,283Archis Bagati · Pyrojas Inc · R44 · FY2025 · CA
Rational Integration of Polygenic Risk Scores (RIPS)
$999,221Josh F. Peterson · Vanderbilt University Medical Center · R01 · FY2022 · HG
Directed Transport Physics and Muli-Scale Therapy of Colon Cancer Liver Metatasis
$999,213Mauro Ferrari · Methodist Hospital Research Institute · U54 · FY2012 · CA
Fox Chase Clinical Epidemiology and Validation Center
$999,093Paul F. Engstrom · Fox Chase Cancer Center · U01 · FY2006 · CA
MRI: Acquisition of a Next Generation, Data-Centric Supercomputer
$999,000Christopher D Carothers · Rensselaer Polytechnic Institute · · FY2018 · CSE
Real-time Multimodal Diffuse Reflectance and Polarization Imaging Based Nerve Identification in Surgical Field of View
$998,991Justin Baba · Yaya Scientific, Llc · R42 · FY2023 · EB
DoseRT⢠: A Non-Contact Optical Patient and Beam Dosimetry System for Continuous in vivo Radiotherapy Verification
$998,974William Ware · Doseoptics, Llc · R44 · FY2024 · CA
DoseRT⢠: A Non-Contact Optical Patient and Beam Dosimetry System for Continuous in vivo Radiotherapy Verification
$998,974William Ware · Doseoptics, Llc · R44 · FY2025 · CA
Development of CD4 TCR-engineered T cell immunotherapy in triple-negative breast cancer
$998,971Yicheng Wang · Immunova Therapeutics, Llc · R44 · FY2025 · CA
OTHER FUNCTIONS "DEVELOPMENT OF A UNI-DIRECTIONAL BRACHYTHERAPY DEVICE FOR THE T
$998,964Kristy Perez · Civatech Oncology, Inc. · N44 · FY2012 · CA
Commercializing Praedicare Dx TM platform for guiding cancer treatments
$998,807Michael H Cardone · Eutropics Pharmaceuticals, Inc. · R44 · FY2017 · CA
TGF-betas in breast cancer progression
$998,687Lalage Wakefield · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
MULTI-DISCIPLINARY RESEARCH AND TRAINING PROGRAM IN BREAST CANCER MOLECULAR IMAGING AND TARGETED RADIOCHEMISTRY
$998,672Trustees Of The University Of Pennsylvania, The · · FY2014 · Department of Energy